Abstract:Colorectal cancer (CRC) is a heterogeneous disease and one of the most prevalent malignancies worldwide. Previous research has demonstrated that mitophagy is crucial to developing colorectal cancer. This study aims to examine the association between mitophagy-related genes and the prognosis of CRC patients. Gene expression profiles and clinical information of CRC patients were obtained from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. Univariate Cox regression and the least absolute shrinkage and selection operator (LASSO) regression analysis were applied to establish a prognostic signature using mitophagy related genes. Kaplan-Meier and receiver operating characteristic (ROC) curves were used to analyze patient survival and predictive accuracy. Meanwhile, we also used the Genomics of Drug Sensitivity in Cancer (GDSC) database and Tumor Immune Dysfunction and Exclusion (TIDE) algorithm to estimate the sensitivity of chemotherapy, targeted therapy and immunotherapy. ATG14 overexpression plasmid was used to regulate the ATG14 expression level in HCT116 and SW480 cell lines, and cell counting kit-8, colony formation and transwell migration assay were performed to validate the function of ATG14 in CRC cells. A total of 22 mitophagy-driven genes connected with CRC survival were identified, and then a novel prognostic signature was established based on 10 of them (AMBRA1, ATG14, MAP1LC3A, MAP1LC3B, OPTN, VDAC1, ATG5, CSNK2A2, MFN1, TOMM22). Patients were divided into high-risk and low-risk groups based on the median risk score, and the survival of patients in the high-risk group was significantly shorter in both the training cohort and two independent cohorts. ROC curve showed that the area under the curves (AUC) of 1-, 3- and 5-year survival were 0.66, 0.66 and 0.64, respectively. Multivariate Cox regression analysis confirmed the independent prognostic value of the signature. Then we constructed a Nomogram combining the risk score, age and M stage, which had a concordance index of survival prediction of 0.77 (95% CI 0.71-0.83) and more robust predictive accuracy. Results showed that CD8+ T cells, regulatory T cells and activated NK cells were significantly more enriched in the high-risk group. Furthermore, patients in the high-risk group are more sensitive to targeted therapy or chemotherapy, including bosutinib, elesclomol, lenalidomide, midostaurin, pazopanib and sunitinib, while the low-risk group is more likely to benefit from immunotherapy. Finally, in vitro study confirmed the oncogenic significance of ATG14 in both HCT116 and SW480 cells, whose overexpression increased CRC cell proliferation, colony formation, and migration. In conclusion, we developed a novel mitophagy-related gene signature that can be utilized not only as an independent predictive biomarker but also as a tool for tailoring personalizing treatment for CRC patients, and we confirmed ATG14 as a novel oncogene in CRC.

Multi gene mutation signatures in colorectal cancer patients: predict for the diagnosis, pathological classification, staging and prognosis

A Mutational Signature That Predicts Prognosis and Benefit of Immune Checkpoint Blockade in Colorectal Cancer

Novel recurrently mutated genes and a prognostic mutation signature in colorectal cancer

Comprehensive genomic profiling reveals prognostic signatures and insights into the molecular landscape of colorectal cancer

Gene Mutation Profiling in Chinese Colorectal Cancer Patients and Its Association with Clinicopathological Characteristics and Prognosis

Identification and Validation of a Novel DNA Damage and DNA Repair Related Genes Based Signature for Colon Cancer Prognosis

Prognostic Impact Of Mutation Profiling In Chinese Patients With Colorectal Liver Metastases.

Application of RNA Processing Factors for Predicting Clinical Outcomes in Colon Cancer.

Mutation patterns in colorectal cancer and their relationship with prognosis

Prognostic genome and transcriptome signatures in colorectal cancers

Correlation between NGS panel-based mutation results and clinical information in colorectal cancer patients

A mitophagy-related gene signature associated with prognosis and immune microenvironment in colorectal cancer

Gene Mutational Clusters in the Tumors of Colorectal Cancer Patients With a Family History of Cancer

A signature based on 11 autophagy genes for prognosis prediction of colorectal cancer

A Novel Prognostic Signatures Based on Metastasis- and Immune-Related Gene Pairs for Colorectal Cancer.

Development and Validation of an 8-Gene Signature to Improve Survival Prediction of Colorectal Cancer

Gene Expression Signature to Predict Prognosis and Adjuvant Chemosensitivity of Colorectal Cancer Patients

Relationship between important gene mutations and clinicopathological characteristics and prognosis in patients of colorectal cancer

Identification and Validation of Prognosis-Associated DNA Repair Gene Signatures in Colorectal Cancer

A Cohort Study on the Molecular Mechanism of Distinct Therapeutic Effects and Prognosis in Chinese Colorectal Cancer Patients Who Underwent Neoadjuvant or Surgical Therapies.

High‐risk Stage III colon cancer patients identified by a novel five‐gene mutational signature are characterized by upregulation of IL‐23A and gut bacterial translocation of the tumor microenvironment